Kodiak Sciences INC Form 4 insider transactions

John A. Borgeson, Chief Financial Officer of Kodiak Sciences Inc., received 66,500 shares of common stock on July 15, 2026.

Victor Perlroth, Chairman and CEO, a Director and 10% owner of Kodiak Sciences Inc., received 100,000 shares of common stock on July 15, 2026.

Kodiak Sciences Inc. reports that Director Taiyin Yang acquired stock options under a Rule 10b5-1(c) plan.

Kodiak Sciences Inc. reports a Form 4 filing detailing stock option grants to Director Robert Profusek.

Kodiak Sciences Inc. reports that Director Richard S. Levy was granted stock options for 17,731 shares of common stock.

Kodiak Sciences Inc. reports that Director Bassil Dahiyat acquired stock options, with vesting contingent on continued service.

Kodiak Sciences Inc. reports that Director Charles Bancroft acquired stock options valued at $38.96 per share.

Kodiak Sciences CFO John A. Borgeson exercised 30,000 stock options and subsequently sold the shares under a 10b5-1 trading plan.

Kodiak Sciences CFO John A. Borgeson exercised options to acquire 28,614 shares of common stock.

Kodiak Sciences Inc. CFO John A. Borgeson reported transactions involving the sale of common stock and the acquisition of stock options under a pre-arranged 10b5-1 trading plan.

Kodiak Sciences Inc.'s Chairman and CEO, Victor Perlroth, acquired 300,000 shares of common stock through the exercise of stock options at $1.04 per share.

Kodiak Sciences Inc. Chairman and CEO Victor Perlroth was granted 175,000 performance-based stock options with vesting tied to future stock price targets.

Baker Bros. Advisors and affiliated funds significantly increased their beneficial ownership in Kodiak Sciences Inc. by purchasing over 2.6 million shares at $23.00 each in an underwritten offering.

John A. Borgeson, an officer at Kodiak Sciences Inc., was granted 250,000 stock options with a vesting schedule tied to continuous service.

Kodiak Sciences Inc. Chairman and CEO Victor Perlroth was granted 340,000 stock options with an exercise price of $3.95, vesting over four years.

Baker Bros. Advisors and affiliated entities, including directors Felix and Julian Baker, reported the acquisition of 40,000 non-qualified stock options in Kodiak Sciences Inc. granted to Felix J. Baker as part of his director compensation.

Kodiak Sciences Inc. Director Robert Profusek was granted 40,000 stock options with an exercise price of $3.73, vesting upon continued service.

Kodiak Sciences Inc. Director Taiyin Yang was granted 40,000 stock options with an exercise price of $3.73, vesting upon continued service.

Kodiak Sciences Inc. director Richard S. Levy was granted 40,000 stock options with an exercise price of $3.73, vesting upon continued service.

Kodiak Sciences Inc. Director Charles A. Bancroft was granted 40,000 stock options with an exercise price of $3.73, aligning his interests with long-term shareholder value.

Kodiak Sciences Inc. Director Bassil I. Dahiyat was granted 40,000 stock options with an exercise price of $3.73, vesting upon continued service.

Kodiak Sciences Inc.'s Executive Vice President and Chief Financial Officer, John A. Borgeson, reported the vesting of restricted stock units and a subsequent 'sell to cover' transaction for tax obligations.

John A. Borgeson, CFO of Kodiak Sciences, was granted stock options for 334,500 shares on August 5, 2024, vesting monthly over four years.

Victor Perlroth, Chairman and CEO of Kodiak Sciences Inc., acquired 406,000 stock options on August 5, 2024, according to a Form 4 filing with the SEC.

Baker Bros. Advisors LP reports the acquisition of 40,000 non-qualified stock options in Kodiak Sciences Inc. on June 28, 2024, with Felix J. Baker receiving the grant as a director.

Director Taiyin Yang reports acquisition of 40,000 stock options in Kodiak Sciences Inc.

Robert Profusek, a director of Kodiak Sciences Inc., acquired 40,000 stock options on June 28, 2024, according to a Form 4 filing with the SEC.

Director Richard S. Levy acquired 40,000 stock options in Kodiak Sciences Inc. on June 28, 2024.

Bassil I. Dahiyat, a director of Kodiak Sciences Inc., acquired 40,000 stock options on June 28, 2024, exercisable at $2.35.

Director Charles Bancroft acquired 40,000 stock options in Kodiak Sciences Inc. on June 28, 2024.